Oral contraceptives and antithrombin III: Variations by dosage and ABO blood group

Ronald T. Burkman; William R. Bell; Howard A. Zacur; Allyn W. Kimball

doi:10.1016/0002-9378(91)91424-U

Oral contraceptives and antithrombin III: Variations by dosage and ABO blood group

Ronald T. Burkman, William R. Bell, Howard A. Zacur, Allyn W. Kimball

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

A randomized clinical trial of oral contraceptives evaluated 67 women on a regimen of 50 μg ethinyl estradiol and 1.0 mg norethindrone, 61 women on a regimen of 35 Kg ethinyl estradiol and 1.0 mg norethindrone, and 64 women on a regimen of 35 μg ethinyl estradiol and 0.5 mg norethindrone. ABO blood group type was determined in all women. At baseline and at 3, 6, and 9 months, plasma antithrombin III levels, by both an immunologic and an activity method, and selected plasma levels of the contraceptive steroids were measured. Antithrombin III levels for all oral contraceptive groups combined decreased from baseline by 19.7% and 28.8% for the immunologic and activity methods, respectively. Analysis of interrelationships among antithrombin III by activity method, oral contraceptive type, and ABO blood group showed larger declines in antithrombin III for type O women using the highest estrogen dose preparation (31.6%) and for non-type O women using the lowest progestin dose preparation (38.9%). Plasma levels of contraceptive steroids also were related to changes in the most extreme levels of antithrombin III.

Original language	English (US)
Pages (from-to)	1453-1460
Number of pages	8
Journal	American journal of obstetrics and gynecology
Volume	164
Issue number	6 PART 1
DOIs	https://doi.org/10.1016/0002-9378(91)91424-U
State	Published - Jun 1991

Keywords

ABO blood group
Oral contraceptives
antithrombin 111

ASJC Scopus subject areas

Obstetrics and Gynecology

Access to Document

10.1016/0002-9378(91)91424-U

Cite this

@article{9ec8fae9c9184c0f82ca14145f9aecf2,

title = "Oral contraceptives and antithrombin III: Variations by dosage and ABO blood group",

abstract = "A randomized clinical trial of oral contraceptives evaluated 67 women on a regimen of 50 μg ethinyl estradiol and 1.0 mg norethindrone, 61 women on a regimen of 35 Kg ethinyl estradiol and 1.0 mg norethindrone, and 64 women on a regimen of 35 μg ethinyl estradiol and 0.5 mg norethindrone. ABO blood group type was determined in all women. At baseline and at 3, 6, and 9 months, plasma antithrombin III levels, by both an immunologic and an activity method, and selected plasma levels of the contraceptive steroids were measured. Antithrombin III levels for all oral contraceptive groups combined decreased from baseline by 19.7% and 28.8% for the immunologic and activity methods, respectively. Analysis of interrelationships among antithrombin III by activity method, oral contraceptive type, and ABO blood group showed larger declines in antithrombin III for type O women using the highest estrogen dose preparation (31.6%) and for non-type O women using the lowest progestin dose preparation (38.9%). Plasma levels of contraceptive steroids also were related to changes in the most extreme levels of antithrombin III.",

keywords = "ABO blood group, Oral contraceptives, antithrombin 111",

author = "Burkman, {Ronald T.} and Bell, {William R.} and Zacur, {Howard A.} and Kimball, {Allyn W.}",

note = "Funding Information: From the Department of Gynecology-Obstetrics, Henry Ford Hospital,' and the Departments of Medicine/ Gynecology and Obstetrics,' and Biostatistics/ The Johns Hopkins Medical Institutions. Supported by a contract from the Contraceptive Evaluation Branch, Center for Population Research, National Institute of Child Health and Human Development, Bethesda, Maryland. Presented at the Fifty-eighth Annual Meeting of the Central Association of Obstetricians and Gynecologists, Louisville, Kentucky, October 11-13,1990. Reprint requests: Ronald T. Burkman, MD, Chairman, Depart. of Gynecology-Obstetrics, Henry Ford Hospital, 2799 W. Grand Blvd., Detroit, MI 48202. 6/6/28212",

year = "1991",

month = jun,

doi = "10.1016/0002-9378(91)91424-U",

language = "English (US)",

volume = "164",

pages = "1453--1460",

journal = "American Journal of Obstetrics and Gynecology",

issn = "0002-9378",

publisher = "Mosby Inc.",

number = "6 PART 1",

}

TY - JOUR

T1 - Oral contraceptives and antithrombin III

T2 - Variations by dosage and ABO blood group

AU - Burkman, Ronald T.

AU - Bell, William R.

AU - Zacur, Howard A.

AU - Kimball, Allyn W.

N1 - Funding Information: From the Department of Gynecology-Obstetrics, Henry Ford Hospital,' and the Departments of Medicine/ Gynecology and Obstetrics,' and Biostatistics/ The Johns Hopkins Medical Institutions. Supported by a contract from the Contraceptive Evaluation Branch, Center for Population Research, National Institute of Child Health and Human Development, Bethesda, Maryland. Presented at the Fifty-eighth Annual Meeting of the Central Association of Obstetricians and Gynecologists, Louisville, Kentucky, October 11-13,1990. Reprint requests: Ronald T. Burkman, MD, Chairman, Depart. of Gynecology-Obstetrics, Henry Ford Hospital, 2799 W. Grand Blvd., Detroit, MI 48202. 6/6/28212

PY - 1991/6

Y1 - 1991/6

N2 - A randomized clinical trial of oral contraceptives evaluated 67 women on a regimen of 50 μg ethinyl estradiol and 1.0 mg norethindrone, 61 women on a regimen of 35 Kg ethinyl estradiol and 1.0 mg norethindrone, and 64 women on a regimen of 35 μg ethinyl estradiol and 0.5 mg norethindrone. ABO blood group type was determined in all women. At baseline and at 3, 6, and 9 months, plasma antithrombin III levels, by both an immunologic and an activity method, and selected plasma levels of the contraceptive steroids were measured. Antithrombin III levels for all oral contraceptive groups combined decreased from baseline by 19.7% and 28.8% for the immunologic and activity methods, respectively. Analysis of interrelationships among antithrombin III by activity method, oral contraceptive type, and ABO blood group showed larger declines in antithrombin III for type O women using the highest estrogen dose preparation (31.6%) and for non-type O women using the lowest progestin dose preparation (38.9%). Plasma levels of contraceptive steroids also were related to changes in the most extreme levels of antithrombin III.

AB - A randomized clinical trial of oral contraceptives evaluated 67 women on a regimen of 50 μg ethinyl estradiol and 1.0 mg norethindrone, 61 women on a regimen of 35 Kg ethinyl estradiol and 1.0 mg norethindrone, and 64 women on a regimen of 35 μg ethinyl estradiol and 0.5 mg norethindrone. ABO blood group type was determined in all women. At baseline and at 3, 6, and 9 months, plasma antithrombin III levels, by both an immunologic and an activity method, and selected plasma levels of the contraceptive steroids were measured. Antithrombin III levels for all oral contraceptive groups combined decreased from baseline by 19.7% and 28.8% for the immunologic and activity methods, respectively. Analysis of interrelationships among antithrombin III by activity method, oral contraceptive type, and ABO blood group showed larger declines in antithrombin III for type O women using the highest estrogen dose preparation (31.6%) and for non-type O women using the lowest progestin dose preparation (38.9%). Plasma levels of contraceptive steroids also were related to changes in the most extreme levels of antithrombin III.

KW - ABO blood group

KW - Oral contraceptives

KW - antithrombin 111

UR - http://www.scopus.com/inward/record.url?scp=0025761476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025761476&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(91)91424-U

DO - 10.1016/0002-9378(91)91424-U

M3 - Article

C2 - 2048592

AN - SCOPUS:0025761476

VL - 164

SP - 1453

EP - 1460

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6 PART 1

ER -

Oral contraceptives and antithrombin III: Variations by dosage and ABO blood group

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this